A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib

NCT06378892 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer Metastatic
ALK Gene Mutation

Interventions

DRUG: Lorlatinib

Sponsor

Centro di Riferimento Oncologico - Aviano